Helix BioPharma Corp.
🇨🇦XTSE.HBPCanadaHealthcare
PriceCA$1.05-0.05 (-4.55%)
Latest anomalies
Neutral 1 detected in the last 120 days
- High: 0
- Medium: 2
- Low: 1
Overnight gap: a gap up from the prior close
Current ratio: below the level we flag as a liquidity warning
Quick ratio: below the level we flag as a liquidity warning
Free with a Finzer account.
Profile
- Healthcare
- Biotechnology
- Canada
Identity
- Exchange
- Toronto Stock Exchange . XTSE
- Type
- Stock
- ISIN
- CA4229101098
- CUSIP
- 422910109
Company
- Employees
- 7
- Headquarters
- Vancouver, Canada
Market
- Shares outstanding
- 76.4M
- Market cap
- CA$80.2M
Highlights
- Market cap
- CA$84.02M
- EPS LTM
- -CA$0.12calculatedCalculated by Finzer, not reported by the data provider.
- P/E LTM
- -8.41calculatedCalculated by Finzer, not reported by the data provider.
- Div yield
- Not reported
Fundamentals (LTM)
- Revenue
- CA$00%unchanged year on year
- Net income
- -CA$9.53M-55.24%down year on year
- Gross margin
- Not reported
- Free cash flow
- -CA$3.93M+34.69%up year on year
Latest news
News is not sourced for this exchange.
Business summary
Helix BioPharma Corp. is a company in the healthcare sector, listed on Toronto Stock Exchange (Canada) under the ticker HBP. Its market capitalisation is CA$80.2M, from 76.4M shares outstanding, as of . Across the 247 trading sessions to the shares traded between CA$0.97 and CA$5.40, and the last close of CA$1.05 sits 2% of the way up that range. The company is headquartered in Vancouver, Canada, and employs about 7 people. The same company also trades as HBP0 on Frankfurt Stock Exchange.
Helix BioPharma Corp. operates as an immune-oncology company in Canada. Its product pipeline comprises L-DOS47, a clinical-stage antibody-enzyme conjugate (AEC) that neutralizes the microenvironment of solid tumors; LDOS001, which is in phase I clinical trial to treat non-small cell lung cancer; LDOS002, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer; LDOS003, which is in phase II clinical trial to treat non-small cell lung cancer; LDOS006, which is in phase Ib/II for the treatment of pancreatic cancer. It develops V-DOS47, an antibody-DOS47 conjugate that targets the vascular endothelial growth factor 2 receptor. It has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. Helix BioPharma Corp. was incorporated in 2008 and is headquartered in Vancouver, Canada.